Clinical Trials
22 trialsNCT04083976 2026-05-04
RAGNAR
Janssen Research & Development, LLC
Phase 2 Completed
NCT05580770 2026-05-01
Mirdametinib + BGB-3245 in Advanced Solid Tumors
SpringWorks Therapeutics, Inc.
Phase 1/2 Terminated
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT05147350 2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1 Terminated
NCT06232408 2025-11-21
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Repare Therapeutics
Phase 1 Terminated
NCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT05072106 2025-09-16
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
PharmaMar
Phase 1 Completed
NCT05014828 2025-08-24
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
BeiGene
Phase 2 Completed
NCT05109442 2025-08-20
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT02836600 2025-08-07
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT04259450 2025-07-17
Study to Assess AFM24 in Advanced Solid Cancers
Affimed GmbH
Phase 1/2 Terminated
NCT04608045 2025-03-03
Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors
CicloMed LLC
Phase 1 Completed
NCT04622774 2025-01-15
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
ImmunoGen, Inc.
Phase 1/2 Completed
NCT05382936 2025-01-09
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors
Stemline Therapeutics, Inc.
Phase 1 Terminated
NCT03154294 2024-07-26
Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT04488003 2024-06-04
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
BioMed Valley Discoveries, Inc
Phase 2 Terminated
NCT04430348 2024-03-12
PTX-35 in Patients With Advanced Solid Tumors
Heat Biologics
Phase 1 Terminated
NCT05051241 2024-03-01
A Study of GFH018 in Patients With Advanced Solid Tumors
Genfleet Therapeutics (Shanghai) Inc.
Phase 1 Completed
NCT04557384 2023-02-27
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT02553499 2019-11-04
MK-1248-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02644278 2019-09-09
First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy
EMD Serono
Phase 1 Completed
NCT01453387 2017-05-08
MSC2015103B in Solid Tumors
EMD Serono
Phase 1 Terminated